Veltion Therapeutic's experienced team of scientists and life science professionals is dedicated to developing novel, potent and specific inhibitors of ATF4 as antitumor agents, specifically lymphoma, lung cancer, and fibrosarcoma.

Select one of the boxes below to learn more about our unique inhibitor, development plan, and who we are.